Ran Mo
Impact in
- Biomaterials top 0.1%
- Nanoparticle-Based Drug Delivery
- Pharmaceutical Science top 0.5%
- Advanced Drug Delivery Systems
Papers in
- Biomaterials 44
- Nanoparticle-Based Drug Delivery 40
-
- Advanced Drug Delivery Systems 7
Ran Mo
101 papers receiving 7.6k citations
Hit Papers
Peers
Comparison fields: 5 of 132
- Biomaterials 3.3k
- Pharmaceutical Science 723
- Biomedical Engineering 3.6k
- Molecular Medicine 252
- Molecular Biology 3.5k
Countries citing papers authored by Ran Mo
This map shows the geographic impact of Ran Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ran Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ran Mo more than expected).
Fields of papers citing papers by Ran Mo
This network shows the impact of papers produced by Ran Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ran Mo. The network helps show where Ran Mo may publish in the future.
Co-authors
The 25 scholars most cited alongside Ran Mo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 4 | |
| 5 | 2023 | 84 | |
| 6 | 2022 | 2 | |
| 7 | A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells Hit paper breakdown → | 2021 | 220 |
| 8 | 2020 | 22 | |
| 9 | 2020 | 25 | |
| 10 | 2020 | 3 | |
| 11 | 2018 | 2 | |
| 12 | 2017 | 16 | |
| 13 | 2017 | 78 | |
| 14 | 2015 | 61 | |
| 15 | 2015 | 153 | |
| 16 | 2013 | 10 | |
| 17 | 2012 | 222 | |
| 18 | 2012 | 44 | |
| 19 | 2011 | 32 | |
| 20 | 1998 | 122 |
About Ran Mo
Ran Mo is a scholar working on Biomaterials, Pharmaceutical Science, Rehabilitation, Biomedical Engineering and Oncology, having authored 110 papers that have together received 7.6k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (40 papers), RNA Interference and Gene Delivery (29 papers), Nanoplatforms for cancer theranostics (28 papers), Graphene and Nanomaterials Applications (11 papers), Advanced biosensing and bioanalysis techniques (9 papers), Advanced Drug Delivery Systems (7 papers), Wound Healing and Treatments (6 papers) and Cancer Cells and Metastasis (6 papers). The work is most often cited by research in Biomaterials (3.3k citations), Pharmaceutical Science (723 citations), Biomedical Engineering (3.6k citations), Molecular Medicine (252 citations) and Molecular Biology (3.5k citations). Ran Mo has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Zhen Gu, Tianyue Jiang, Can Zhang, Wanyi Tai, Shiyang Shen, Qineng Ping, Lingjing Xue, Jingwei Xue, Rocco DiSanto and Wujin Sun. Their work appears in journals such as Biomaterials, Advanced Functional Materials, Nano Letters, Annals of Translational Medicine and Advanced Materials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.